BCL2 and colorectal carcinoma: For example, in recurrent CRC and oxaliplatin (OXA) resistant patients, the upregulated circHIPK3 in tissues promotes oxaliplatin resistance and cancer progression by sponging miR-637, increasing the expression of STAT3, which subsequently activates the downstream Bcl-2/beclin1 signaling pathway102.